Delivery Order SPE2DB24D9238-SPE2DB25FDQRH

Award Date 4/1/25
Potential Completion Date 4/22/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $10,375.53 contract is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a period of performance through April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,458.51 contract is for the supply of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a period of performance through April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,834.04 contract is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a period of performance through April 2, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $10,375.53, is for the provision of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product. The contract has an ultimate completion date of April 21, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $17,292.55, is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $6,917.02 contract is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a period of performance through April 1, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of various pharmaceutical products including NUPLAZID 34 MG CAPSULE 30S. The contract, valued at $6,729.00, has an ultimate completion date of September 19, 2024. DMS Pharmaceutical Group provides a wide range of pharmaceutical items, from common medications to specialized drugs and medical supplies, to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $18,398.16 contract is for the supply of 4562101320 - NUPLAZID 34 MG CAPSULE 30S, with a completion date of September 28, 2023. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,093.50 firm fixed-price contract is for the delivery of 4564884983 - NUPLAZID 34 MG CAPSULE 30S, with a performance period through July 3, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,729 contract is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a performance period through December 12, 2024. The contract is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned...
  • SPE2DB24D9238
    Indefinite Delivery Contract
  • SPE2DB24D9238-SPE2DB25FDQRH
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $10,375.53 contract is for the delivery of NUPLAZID 34 MG CAPSULE 30S, a specialized pharmaceutical product, with a period of performance through April 22, 2025.

DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide. This contract is not associated with a specific set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains.

Additionally, DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a wide range of pharmaceutical items to support the medical supply needs of Department of Defense healthcare sites worldwide.

Generated 7/1/25, 10:10 AM